Publications by authors named "D Tousoulis"
Introduction: Hypertension is associated with changes in microcirculation, while increased blood pressure (BP) during exercise stress testing has been correlated with adverse outcomes.
Aim: To evaluate the relationship of microcirculation with exercise BP response in hypertensive individuals.
Methods: 105 hypertensive individuals underwent exercise stress testing and nail-fold videocapillaroscopy assessment, in order to evaluate the relationship of BP response to exercise with capillary density.
Heart failure (HF) is a major global health challenge, particularly among individuals with type 2 diabetes mellitus (T2DM), who are at significantly higher risk of developing HF. Diabetic cardiomyopathy, a unique form of heart disease, often progresses silently until advanced stages. Recent research has focused on sodium-dependent glucose transporter 2 inhibitors (SGLT2i), originally developed for hyperglycemia, which have shown potential in reducing cardiovascular risks, including HF hospitalizations, irrespective of diabetic status.
View Article and Find Full Text PDFArticle Synopsis
- Heart failure (HF) is a serious health issue that has high rates of illness and death, with electrical conduction problems being a key factor in its progression.
- Conduction system pacing (CSP) is a new treatment method that includes techniques like His bundle pacing and left bundle branch area pacing, recommended for certain patients despite mainly being supported by observational studies.
- There are significant challenges in implementing CSP, such as difficulties with lead implantation and the need for better tools, making future large-scale randomized controlled trials necessary for improving treatment strategies for HF patients.
Heart failure (HF) is a growing concern due to the aging population and increasing prevalence of comorbidities. Despite advances in treatment, HF remains a significant burden, necessitating novel therapeutic approaches. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have emerged as a promising treatment option, demonstrating benefits across the entire spectrum of HF, regardless of left ventricular ejection fraction (LVEF).
View Article and Find Full Text PDF